argenx: Positive Phase 3 ALKIVIA results for efgartigimod in autoimmune myositis

Key highlights
  • ALKIVIA Phase 3 met primary endpoint: 15.4‑point greater mean TIS at Week 52 vs placebo in combined IMNM+DM population (47.95 vs 32.56; p=0.0011).
  • Treatment effect appeared by Week 4 and was sustained through 52 weeks despite protocol-mandated steroid tapering.
  • IMNM subgroup: 14.8‑point TIS improvement vs placebo (45.05 vs 30.24; p=0.0048); DM subgroup: 14.5‑point improvement (51.51 vs 36.96) but not statistically significant (p=0.1093).
  • Efgartigimod was well tolerated with a safety profile consistent with prior studies; all six TIS core measures favored active treatment, including skin improvement in DM.

Topline efficacy

The ALKIVIA Phase 3 study showed that subcutaneous efgartigimod produced a statistically significant and clinically meaningful improvement in mean Total Improvement Score (TIS) at 52 weeks versus placebo in the combined immune‑mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population (47.95 vs 32.56; 15.4‑point difference; p=0.0011).

Onset and durability

Separation from placebo emerged by Week 4 and was maintained through the one‑year treatment period, despite a protocol‑mandated corticosteroid taper, indicating a rapid and sustained treatment effect.

Subtype and clinical measures

Prespecified analyses found a significant benefit in IMNM (14.8‑point TIS advantage; 45.05 vs 30.24; p=0.0048). A similar magnitude of improvement occurred in DM (14.5‑point advantage; 51.51 vs 36.96) but did not reach statistical significance in that smaller cohort (p=0.1093). All six TIS core set measures contributed to the effect, covering muscle strength, physical function and extramuscular disease activity, with skin improvement observed in DM.

Safety, design and next steps

Efgartigimod was well tolerated with a safety profile consistent with prior studies. ALKIVIA was a global randomized, double‑blind, placebo‑controlled Phase 2/3 program that enrolled 264 patients overall (Phase 3 n=175) and included a mandated steroid taper. Detailed results will be presented at a forthcoming medical meeting, and efgartigimod continues to be evaluated in other autoimmune rheumatologic indications.

Source: argenx

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

27 August 2026
argenx acquires Forte Biosciences, adds anti‑CD122 antibody FB102

Adds FB102, a first‑in‑class anti‑CD122 with clinical proof‑of‑concept in vitiligo and celiac disease; $77 per‑share tender offer completed and merger closed.

27 July 2026
argenx to acquire Forte Biosciences, adding anti‑CD122 candidate FB102

FB102 shows Phase 1b proof in vitiligo and celiac; Phase 2 in celiac expected H2 2026. Acquisition executed as $77/share cash tender offer; close targeted Q3 2026.

3 June 2026
argenx: Efgartigimod shows sustained myositis benefit, maintained response in Sjogren’s with consistent safety

ALKIVIA+ 52‑week data show sustained Total Improvement Score gains; RHO+ shows maintained response after switch to biweekly dosing; safety consistent across indications.

8 May 2026
argenx: FDA expands VYVGART/VYVGART Hytrulo approval to all adult gMG patients

Phase-3 ADAPT SERON: VYVGART showed rapid, significant, sustained improvements across anti-MuSK, anti-LRP4 and triple-seronegative gMG; safety consistent; IV/SC options; access support.

23 September 2026
Johnson & Johnson: Model suggests Tec‑Dara may normalize long‑term mortality in early‑line RRMM

Modeling of MajesTEC‑3 trial data estimates a high cure fraction and nearly fourfold median OS benefit for teclistamab plus daratumumab FASPRO versus standard care in relapsed/refractory myeloma.